Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an equity value of $3.7B and an enterprise value of $3.3B. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Boston Scientific management to meet with Oppenheimer
- Boston Scientific Resumes AVANT GUARD Clinical Trial
- Boston Scientific to acquire Cortex, terms undisclosed
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific presents ACURATE neo2 data at TCT 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
